A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Completed · Phase 2 · NCT05104567
Conditions: Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
At a glance
- Research payments reported, 2025
- $6,150
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 138
About the trial
- Sponsor
- Sanofi (with Merck Sharp & Dohme LLC)
- Tested
- THOR-707 (drug), Pembrolizumab (drug), Cetuximab (drug)
- Dates
- Started 2021-12-09; completion 2024-09-09
- Results posted
- Yes
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer. This study is structured as a master protocol for the investigation of SAR444245 with other anticancer therapies. Sub study 01 - Cohort A aims to establish proof-of-concept that combining the non-alpha-IL2 SAR444245 with the anti-PD1 antibody pembrolizumab will result in a significant increase in the percentage of patients experiencing an objective response in the setting of advanced unresectable or me…
From ClinicalTrials.gov, last updated 2025-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $6,150 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.